This is a problem the FDA could easily solve.
The limiting factor is approval of the autoinjector. A device.
The agency has had no problem fast tracking fucked up implantable devices because they are “substantially similar to and not different from” devices already on the market.
Hence the number of medical injury lawsuits.
But they won’t approve a “generic” epipen because the drug has “product exclusivity” due to the actual injector.
That way, Mylan can keep jacking up the price for a drug that costs literal pennies to make.